SORAVE: Sorafenib and everolimus for treatment of patients with relapsed solid tumors and with KRAS mutated NSCLC—A phase I study.

Lucia Nogova,Christian Mattonet,Masyar Gardizi,Matthias Scheffler,Marc Bos,Karin Toepelt,Lukas C. Heukamp,Ahmed Abbas Suleiman,Sebastian Frechen,Fritz Soergel,Uwe Fuhr,Roland Schnell,Ildiko Katay,Dirk Behringer,Thomas Geist,Britta Kaminsky,Martina Eichstaedt,Dirk Tummes,Reinhard Buettner,Jürgen Wolf

SORAVE: Sorafenib and everolimus for treatment of patients with relapsed solid tumors and with KRAS mutated NSCLC—A phase I study.

2017

8112 Background: Dual inhibition of signaling pathways interfering with cell proliferation and angiogenesis may increase anti-tumor efficacy. Sorafenib and mTOR inhibitors showed preliminary activi...

Keywords:

Signal transduction
Angiogenesis
Everolimus
Discovery and development of mTOR inhibitors
Cell growth
Pathology
Cancer research
KRAS
Sorafenib
Medicine
phase i study
dual inhibition

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations